When treating non-small cell lung cancer, doctors use a type of treatment called immune checkpoint inhibitors. To better understand how these patients might fare, researchers looked at 33 different studies involving PET scan data. These scans measure metabolic activity in the body.
The analysis found that while some measurements like SUVmax and SUVmean did not provide clear predictions for survival, others were very telling. Specifically, two metrics called MTV (metabolic tumor volume) and TLG (total lesion glycolysis) showed a strong link to outcomes. Patients with higher levels of these two markers had worse progression-free survival and overall survival.
These findings suggest that tracking specific volumes and activity levels can help identify which patients might face a harder road during treatment. However, it is important to note that one specific measurement for overall survival did not hold up as strongly when other factors were adjusted. These results come from an analysis of existing data rather than a new clinical trial.
